EXT1 and non-small cell lung carcinoma: As expected, the NSCLC samples with high EXT1 expression were shown to significantly associated with worse prognosis (median survival months: 42.3, 95% CI: 36.9‐56.0), compared with the low‐expression group (median survival month: 57.9 95% CI: 57.9‐72.5, P = .00065), as shown in Figure 1A.